The incidence of herpes zoster in China: A meta-analysis and evidence quality assessment

Hum Vaccin Immunother. 2023 Aug 1;19(2):2228169. doi: 10.1080/21645515.2023.2228169. Epub 2023 Jul 9.

Abstract

This review aimed to estimate the disease burden of herpes zoster (HZ) in China and explore the application of the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) approach in studies of disease burden. We searched for the literature of observational studies analyzing HZ incidence in populations of all ages in China. Meta-analysis models were constructed to calculate the pooled incidence of HZ and pooled risks of postherpetic neuralgia (PHN), HZ recurrence, and hospitalization. Subgroup analysis was performed according to gender, age, and quality assessment score. The quality of evidence for incidence was rated using the GRADE system. Twelve studies with a total of 25,928,408 participants were included in this review. The pooled incidence for all ages was 4.28/1000 person years (95% CI 1.22-7.35). It increased with the increasing in age especially for individuals aged ≥60 y, which was 11.69/1000 person years (95% CI 6.56-16.81). The pooled risks of PHN, recurrence, and hospitalization were 12.6% (95% CI 10.1-15.1), 9.7% (95% CI 3.2-16.2), and 6.0/100,000 population (95% CI 2.3-14.2), respectively. The quality of the evidence assessment of the pooled incidence by the GRADE for all ages was 'low'; however, it was 'moderate' for the ≥60 yold subgroup. HZ is a serious public health problem in China and is more significant in individuals older than 60 y. Therefore, an immunization strategy for the zoster vaccine should be considered. The evidence quality assessment by the GRADE approach indicated that we had more confidence in the estimation of aged population.

Keywords: GRADE; Herpes zoster; disease burden; incidence; meta-analysis.

Publication types

  • Meta-Analysis
  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • China / epidemiology
  • Herpes Zoster Vaccine*
  • Herpes Zoster* / epidemiology
  • Herpes Zoster* / prevention & control
  • Herpesvirus 3, Human
  • Humans
  • Incidence
  • Neuralgia, Postherpetic* / epidemiology

Substances

  • Herpes Zoster Vaccine

Grants and funding

This research was supported by Beijing Natural Science Foundation [L202008] in study design, in the collection, analysis and interpretation of data, and in writing the manuscript. The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.